LongeVC, an international investor based in Latvia, has injected an unspecified sum into Cambridge company Constructive Bio ...

The escalating global prevalence of obesity and type 2 diabetes mellitus (T2DM) underscores the urgent need for innovative therapeutic approaches capable of addressing multiple metabolic pathways ...

Nurx, a leading telehealth platform specializing in women's health, is excited to announce an integration agreement with Gifthealth, Eli Lilly and Company's LillyDirect® pharmacy provider, for ...

The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a ...

Mounjaro, a new treatment for Type 2 diabetes and obesity, has been launched in India after CDSCO approval. The drug, ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

India's anti-obesity drug market shows significant growth. It has increased fourfold in five years. Lifestyle diseases and ...

Hearing loss is linked to a heightened risk of developing heart failure, with the psychological distress caused by the impairment taking a key role in the observed association, finds a large long term ...

I RECEIVED a letter from CVS Caremark informing me that effective March 1st, HealthTrust would no longer cover anti-obesity ...

Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.

For patients with inadequately controlled T2D receiving dulaglutide, switching to tirzepatide is associated with additional HbA1c reduction and weight loss.

Researchers have found in a new research that among patients with poorly controlled type 2 diabetes, switching from ...